National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK.
Translational Health Sciences, Bristol Medical School, Southmead Hospital, University of Bristol, Learning & Research Building (Level 1), Bristol, BS10 5NB, UK.
Biometals. 2022 Aug;35(4):785-793. doi: 10.1007/s10534-022-00402-8. Epub 2022 Jun 10.
Serum zinc has been implicated as an important mediator of haemostasis and thrombosis. However, the nature and magnitude of any potential relationship between serum zinc and venous thromboembolism (VTE) is unknown. We aimed to evaluate the prospective association between serum zinc and VTE risk. We analyzed data involving 2472 men aged 42-61 years without a history of VTE in the Kuopio Ischemic Heart Disease population-based cohort study, with the assessment of serum zinc concentrations using atomic absorption spectrometry. Hazard ratios (95% confidence intervals [CIs]) for incident VTE were estimated. A total of 166 VTE cases occurred during a median follow-up of 27.1 years. The risk of VTE per 1 standard deviation increase in serum zinc in analysis adjusted for systolic blood pressure, body mass index, total cholesterol, triglycerides, smoking status, histories of type 2 diabetes and coronary heart disease, medication for dyslipidaemia, alcohol consumption, physical activity, and socioeconomic status was (HR 1.03; 95% CI 0.86-1.22), which remained similar (HR 1.04; 95% CI 0.87-1.23) following further adjustment for inflammation and history of cancer. Comparing the extreme tertiles of serum zinc, the corresponding adjusted HRs (95% CIs) were 0.92 (0.63-1.36) and 0.94 (0.64-1.39), respectively. Imputed results based on 2682 participants and 176 VTE events were consistent with the observed results. In middle-aged and older Finnish men, serum zinc is not associated with future VTE risk. Other large-scale prospective studies conducted in other populations are needed to confirm or refute these findings.
血清锌被认为是止血和血栓形成的重要介质。然而，血清锌与静脉血栓栓塞症（VTE）之间的任何潜在关系的性质和程度尚不清楚。我们旨在评估血清锌与 VTE 风险的前瞻性关联。我们分析了 2472 名年龄在 42-61 岁、无 VTE 病史的男性的 Kuopio 缺血性心脏病人群队列研究数据，使用原子吸收光谱法评估血清锌浓度。使用风险比（95%置信区间[CI]）估计新发 VTE 的风险。在中位数为 27.1 年的随访期间，共发生了 166 例 VTE 病例。在分析中，血清锌每增加 1 个标准差，VTE 的风险比（HR）为 1.03（95%CI 0.86-1.22），这一结果在调整收缩压、体重指数、总胆固醇、甘油三酯、吸烟状况、2 型糖尿病和冠心病病史、血脂异常药物治疗、饮酒、身体活动和社会经济状况后仍然相似（HR 1.04；95%CI 0.87-1.23）。进一步调整炎症和癌症病史后，结果仍然相似。比较血清锌的极端三分位值，相应的调整后 HR（95%CI）分别为 0.92（0.63-1.36）和 0.94（0.64-1.39）。基于 2682 名参与者和 176 例 VTE 事件的推断结果与观察结果一致。在中年和老年芬兰男性中，血清锌与未来 VTE 风险无关。需要在其他人群中开展其他大规模前瞻性研究来证实或反驳这些发现。
